Real-World Data on the Effects of Cardiac Resynchronization Therapy in Adult Patients With Congenital Heart Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Cardiac resynchronization therapy: Cardiac resynchronization therapy pacemaker or defibrillator with a transvenous or epicardial systemic ventricle lead
Study summary
This study aims to evaluate the real-world effects of cardiac resynchronization therapy (CRT) in adult patients with congenital heart disease (ACHD). Specifically, it seeks to determine whether CRT improves clinical outcomes in this unique patient population and to identify factors associated with a favorable response to therapy.
Eligibility
Primary outcome measure(s)
- QRS duration — From enrollment through study completion, with an average follow-up duration of 1 year.
Evaluation of the longitudinal effect of CRT on the duration (in ms) of the QRS interval on surface ECG - Systemic ventricle function class — From enrollment through study completion, with an average follow-up duration of 1 year.
Evaluation of the longitudinal effect of CRT on the echocardiographic functional classification of the systemic ventricle (i.e., normal, mildly reduced, moderately reduced, severely reduced) - NYHA functional class — From enrollment through study completion, with an average follow-up duration of 1 year.
Evaluation of the longitudinal effect of CRT on the NYHA functional classification (i.e., Class I, II, III, IV)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Leiden University Medical Center (LUMC) | Leiden | South Holland | Recruiting |
More Leiden University Medical Center trials in the Netherlands
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06969924 on ClinicalTrials.gov ↗ ← All trials in the Netherlands